Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, Phase II trial designed to estimate in terms of PFS the
efficacy of cabozantinib, given as second- or third- line treatment in HCC patients that
progress on or are intolerant to immune checkpoint inhibitors, including anti-PD-1 and
anti-PD-L1 antibodies.